摘要
目的探讨晚期结肠癌患者经标准治疗失败后行呋喹替尼、程序性死亡受体-1(PD-1)单抗联合方案治疗的效果。方法选取福建医科大学附属漳州市医院肿瘤内科2021年1月至2024年10月标准治疗失败后晚期结肠癌患者80例,以随机数字表法分组,对照组(40例)行呋喹替尼治疗,观察组(40例)基于对照组联合PD-1单抗治疗,对比两组疗效、胃肠功能、肿瘤标志物、免疫功能、不良反应。结果观察组客观缓解率、疾病控制率较对照组高,首次排气和排便以及肠鸣音消退时间较对照组短(P<0.05)。治疗后,观察组CA19-9、CEA、CA125水平较对照组低(P<0.05);观察组CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+)水平较对照组优(P<0.05)。两组不良反应发生情况比较,差异无统计学意义(P>0.05)。结论晚期结肠癌患者经标准治疗失败后行呋喹替尼、PD-1单抗联合方案治疗的效果显著,不仅可以调节改善患者机体免疫功能状态,还能对其胃肠功能加以改善。
Objective To investigate the efficacy of a combination therapy of fruquintinib and programmed death receptor-1(PD-1)monoclonal antibody in patients with advanced colon cancer who have failed standard treatment.Methods Eighty patients with advanced colon cancer after standard treatment failure were included in the Department of Medical Oncology,Zhangzhou Hospital,Fujian Medical University,from January 2021 to October 2024,and were grouped by the random number table method,with the control group(40 cases)treated with furaquintinib,and the observation group(40 cases)treated with PD-1 monoclonal antibody based on the combination of the control group,to compare and analyse the two groups in terms of their clinical efficacy,gastrointestinal function,tumour markers and immune function and the occurrence of adverse reactions.Results The observation group showed a higher ORR and DCR,along with shorter times to first flatus,defecation,and bowel sound disappearance compared to the control group(P<0.05).After treatment,the observation group had lower levels of CA19-9,CEA,and CA125 than the control group(P<0.05).Additionally,the observation group demonstrated better CD4^(+),CD8^(+),and CD4^(+)/CD8^(+)levels compared to the control group(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions The combination therapy of fruquintinib and PD-1 monoclonal antibody has a significant effect on the treatment of advanced colon cancer patients after standard treatment failure.It can not only regulate and improve the patient’s immune function status,but also improve their gastrointestinal function.
作者
林淑君
黄巧娜
郑玲真
LIN Shujun;HUANG Qiaona;ZHENG Lingzhen(Department of Medical Oncology,Zhangzhou Affiliated Hospital of Fujian Medical University,Zhangzhou,Fujian 363000,China)
出处
《中国医药指南》
2025年第20期24-27,共4页
Guide of China Medicine
